secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bluejay Diagnostics, Inc. (BJDX)
CIK:        0001704287
Form:       8-K
Filed at:   2023-08-16T23:59:59+00:00
Accession:  0001213900-23-067990
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bluejay Diagnostics H1 2023 net loss $5.4M; cash down to $5.1M; FDA meeting on IL-6 test
--------------------------------------------------------------------------------

- Net loss $5.4M ($5.24/sh) vs $4.0M ($2.00/sh) in H1 2022; no revenue reported.
- Cash and equivalents fell to $5.1M from $10.1M at Dec 31, 2022; company expects to raise capital near-term.
- R&D expense doubled to $3.0M, driven by clinical trial costs for Symphony IL-6 sepsis test.
- FDA pre-submission meeting on Aug 11, 2023 confirmed 510(k) pathway; company targets submission in H1 2024.
- Sales and marketing expense $302K vs $135K in prior period as company builds commercial infrastructure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704287/000121390023067990/0001213900-23-067990-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704287/000121390023067990/ea183606-8k_bluejay.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-067990

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer